SANTA ANA, Calif., January 21, 2025: FUJIFILM Irvine Scientific, Inc., a global leader in the innovation and manufacture of cell culture solutions for the life science and medical markets, today announced it entered into an agreement to sell its Medical Media Business Unit (MBU) to Astorg, a leading pan-European private equity firm with an extensive track record in global healthcare investments. This strategic acquisition builds on Astorg’s recent take-private of Hamilton Thorne, and simultaneous acquisition of Cook Medical’s Reproductive Health business (“Cook Medical RH”), expanding the product portfolio of Astorg’s new global MedTech company serving the assisted reproductive technology (ART) and IVF industry. The sale is expected to close on April 1, 2025.
As part of the Life Sciences Business Division of FUJIFILM Corporation, FUJIFILM Irvine Scientific is focused on being a trusted supplier to the life science market. The MBU consists of products used for in vitro fertilization (IVF), infertility research, and cytogenetic analysis. The MBU is distinct from all other Fujifilm Healthcare businesses including Life Sciences. The sale of the MBU will accelerate future investments towards market growth and further enhance FUJIFILM Irvine Scientific’s focus and commitment to meet the needs of all who work in life sciences to enrich the lives of people through innovative, accessible therapies.
“After careful consideration, we made a strategic decision to sell the MBU because we recognized the different trajectories and needs of our businesses. This move allows for continued focus on our life sciences businesses within Fujifilm, and for the MBU to thrive under Astorg,” said Tim Mullane, president, FUJIFILM Irvine Scientific. “Astorghas demonstrated a strong commitment to building capabilities to support the IVF market. We will work closely with Astorg to ensure a smooth transition of the MBU and seamless support for global IVF customers.”
FUJIFILM Irvine Scientific and Astorg are working actively on an integration plan to meet the needs of current medical media customers and partners. It is anticipated the transition between the two companies will be completed by January 2026.
ENDS
FUJIFILM Irvine Scientific
FUJIFILM Irvine Scientific, Inc. is a global leader in the innovation and manufacture of cell culture solutions for Life Science and Medical markets, providing products and services that assist customers in advancing healthcare initiatives. Working across discovery research, cell and gene therapy, reproductive medicine and cytogenetics, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers, manufacturers, and clinicians worldwide.
For over 50 years, FUJIFILM Irvine Scientific’s mission has been to empower all who bring medicines and treatments to life with unmatched quality and responsiveness in its products and custom solutions, providing customers with the vital resources needed to enrich human lives through innovative, accessible therapies. The Company’s facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Irvine Scientific, Inc. is a subsidiary of FUJIFILM Holdings America Corporation reporting to FUJIFILM Holdings Corporation.
For more information, please visit: www.irvinesci.com.
FUJIFILM Holdings Corporation
FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a USD collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.
For further details about our commitment to sustainability and Fujifilm’s Sustainable Value Plan 2030, click here.
Astorg
Astorg is a leading pan-European private equity firm with over €23 billion of assets under management. Astorg works with entrepreneurs and management teams to acquire market leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance and capital they need to achieve their growth goals. Enjoying a distinct entrepreneurial culture, a long-term shareholder perspective and a lean decision-making body, Astorg has valuable industry expertise in healthcare, software, technology, business services and technology-based industrial companies. Headquartered in Luxembourg, Astorg has offices in London, Paris, New York, Frankfurt, and Milan.
For more information about Astorg: www.astorg.com
Media Contact:
Lori Serles
FUJIFILM Irvine Scientific
(949) 261-7800
lori.serles@fujifilm.com